Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
- 29 May 2021
- journal article
- review article
- Published by Wiley in Advanced Materials
- Vol. 33 (27) , 2007576
Abstract
The discovery of immune checkpoint blockade has revolutionized the field of immuno‐oncology and established the foundation for developing various new therapies that can surpass conventional cancer treatments. Most recent immunotherapeutic strategies have focused on adaptive immune responses by targeting T cell‐activating pathways, genetic engineering of T cells with chimeric antigen receptors, or bispecific antibodies. Despite the unprecedented clinical success, these T cell‐based treatments have only benefited a small proportion of patients. Thus, the need for the next generation of cancer immunotherapy is driven by identifying novel therapeutic molecules or new immunoengineered cells. To maximize the therapeutic potency via innate immunogenicity, the convergence of innate immunity‐based therapy and biomaterials is required to yield an efficient index in clinical trials. This review highlights how biomaterials can efficiently reprogram and recruit innate immune cells in tumors and ultimately initiate activation of T cell immunity against advanced cancers. Moreover, the design and specific biomaterials that improve innate immune cells’ targeting ability to selectively activate immunogenicity with minimal adverse effects are discussed.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01 NS104315)
- Cancer Prevention and Research Institute of Texas (RR180017)
- National Cancer Institute (K08 CA241070)
- Cancer Prevention and Research Institute of Texas
This publication has 198 references indexed in Scilit:
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature Medicine, 2013
- Mechanisms of Action of AdjuvantsFrontiers in Immunology, 2013
- Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigensNature Biotechnology, 2012
- Toll-Like Receptor 7 Agonist Therapy with Imidazoquinoline Enhances Cancer Cell Death and Increases Lymphocytic Infiltration and Proinflammatory Cytokine Production in Established Tumors of a Renal Cell Carcinoma Mouse ModelJournal of Oncology, 2012
- The pharmacokinetics of Toll-like receptor agonists and the impact on the immune systemExpert Review of Clinical Pharmacology, 2011
- Enhanced in-vitro transfection and biocompatibility of l-arginine modified oligo (-alkylaminosiloxanes)-graft-polyethylenimineBiomaterials, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- A cell biological view of Toll-like receptor function: regulation through compartmentalizationNature Reviews Immunology, 2009
- DNA vaccines: precision tools for activating effective immunity against cancerNature Reviews Cancer, 2008
- Toll-like receptor signallingNature Reviews Immunology, 2004